Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 1.00 |
| ▸ | CCR5 | P51681 | 3/20 | 1.00 |
| ▸ | CCR8 | P51685 | 3/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | METAP2 | P50579 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.55 |
| ▸ | NOS2 | P35228 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abametapir SCHEMBL29374261 | 1.00 | CCR1 (1.00) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL14804379 | 0.94 | CCR1 (0.89) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL1456103 | 0.92 | CCR1 (0.84) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL14804380 | 0.87 | CCR1 (0.76) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL17051514 | 0.86 | CCR1 (0.75) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL17051502 | 0.85 | CCR1 (0.73) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL14804374 | 0.85 | CCR1 (0.73) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL28454095 | 0.85 | CCR1 (0.73) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL8025640 | 0.85 | CCR1 (0.73) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL16656145 | 0.85 | CCR1 (0.73) | CCR1CCR5CCR8HDAC6METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 897 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727953-A2 | ACCELERATED MARKING OF 5-FORMYL CYTOSINE AND USE IN NUCLEIC ACID METHYLATION SEQUENCING | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20250375511-A1 | METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | claimed |
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | claimed |
| US-20250114456-A1 | ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS | THERALASE TECHNOLOGIES, INC. (CA) | 2025-04-10 | — | — | US | claimed |
| CN-119587710-A | Application of charge crosslinked carrier as tumor chemotherapeutic medicine | 中山大学 | 2025-03-11 | — | — | CN | claimed |
| WO-2024256358-A2 | ACCELERATED MARKING OF 5-FORMYL CYTOSINE AND USE IN NUCLEIC ACID METHYLATION SEQUENCING | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-19 | — | — | WO | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240327324-A1 | METHOD FOR PRODUCING FATTY ALDEHYDES AND DERIVATIVES THEREOF | FMC Agricultural Solutions A/S (DK) | 2024-10-03 | — | — | US | claimed |
| US-20240269066-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | PRECVISION BIOTECHNOLOGIES LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| CN-114569612-B | Application of bipyridine in preventing and treating silkworm maggot disease | 江苏科技大学 | 2024-02-27 | — | — | CN | claimed |
| EP-0728791-B1 | Process for the preparation of copolymers based on carbon monoxide and at least one compound having an alkenylic unsaturation | ENICHEM SPA (IT) | 1999-06-23 | — | — | EP | claimed |
| EP-0894783-A1 | Process for the synthesis of phenol from benzene | Enichem S.p.A. (IT) | 1999-02-03 | — | — | EP | claimed |
| US-5783164-A | PALLADIUM CATALYST WITH A NITROGENATED LIGAND STABLE TO OXIDATION | ENICHEM S.P.A. (IT) | 1998-07-21 | — | — | US | claimed |
| US-5739264-A | Process for the preparation of copolymers based on carbon monoxide and at least one compound having an alkenylic unsaturation | ENICHEM S.P.A. (IT) | 1998-04-14 | — | — | US | claimed |
| US-5734010-A | Process for the preparation of copolymers of carbon monoxide and at least one compound containing an alkenyl unsaturation | ENICHEM S.P.A. (IT) | 1998-03-31 | — | — | US | claimed |
| US-5717060-A | Process for the preparation of copolymers based on carbon monoxide and at least one compound containing an alkenyl unsaturation | ENICHEM S.P.A. (IT) | 1998-02-10 | — | — | US | claimed |
| EP-0808796-A1 | Process for the preparation of hydrogen peroxide | ENICHEM S.p.A. (IT) | 1997-11-26 | — | — | EP | claimed |
| EP-0802213-A2 | Process for the preparation of copolymers of carbon monoxide and at least one compound containing an alkenyl unsaturation | ENICHEM S.p.A. (IT) | 1997-10-22 | — | — | EP | claimed |
| EP-0774479-A2 | Process for the preparation of copolymers based on carbon monoxide and at least one compound containing an alkenyl unsaturation | ENICHEM S.p.A. (IT) | 1997-05-21 | — | — | EP | claimed |
| EP-0728791-A1 | Process for the preparation of copolymers based on carbon monoxide and at least one compound having an alkenylic unsaturation | ENICHEM S.p.A. (IT) | 1996-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | CD4, TPMT, SLC11A2 | CCR1 70/4885CCR5 119/4885CCR8 193/4885 |
| US-20250114456-A1 | ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS | PDCD1, CD47, CD274 | CCR1 471/4885CCR5 2069/4885CCR8 903/4885 |
| US-20250375511-A1 | METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS | NFATC1, PCNA, PHPT1 | CCR1 2081/4885CCR5 3447/4885CCR8 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.